Cargando…
Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis
INTRODUCTION: Psoriatic arthritis (PsA) is a complex and heterogeneous inflammatory disease. Secukinumab, a biologic disease-modifying antirheumatic drug (bDMARD), has extensive clinical evidence of efficacy and safety in the treatment of PsA but data in clinical practice are still limited. This stu...
Autores principales: | Alegre-Sancho, Juan José, Núñez-Monje, Victoria, Campos-Fernández, Cristina, Balaguer-Trull, Isabel, Robustillo-Villarino, Montserrat, Aguilar-Zamora, Marta, Garijo-Bufort, Marta, Pedraz-Penalva, Teresa, Peña-González, Carolina, de la Morena, Isabel, Bedoya-Sanchís, Diego, Yankova-Komsalova, Liliya, Conesa-Mateos, Arantxa, Martinez-Cristóbal, Anna, Navarro-Blasco, Francisco Javier, Senabre-Gallego, Jose Miguel, Sivera, Francisca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694458/ http://dx.doi.org/10.3389/fmed.2023.1294247 |
Ejemplares similares
-
Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum
por: Sivera, Francisca, et al.
Publicado: (2023) -
Predictive values of inflammatory back pain, positive HLA B27 antigen and acute and chronic magnetic resonance changes in early diagnosis of Spondyloarthritis. A study of 133 patients
por: Komsalova, Liliya Yankova, et al.
Publicado: (2020) -
Respiratory syncytial virus outbreak during the COVID-19 pandemic. How has it changed?
por: Hernández-Rivas, Lucía, et al.
Publicado: (2023) -
Respiratory syncytial virus outbreak during the COVID-19 pandemic. How has it changed?
por: Hernández-Rivas, Lucía, et al.
Publicado: (2023) -
Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study
por: Alonso, Sara, et al.
Publicado: (2021)